Christopher Cassella

ID: 1b83bbcc-2619-30fb-68c4

/

Unclaimed

/

Organization: Goodwin Procter

FDA Approves EYLEA® (Aflibercept) for Treatment of Retinopathy of Prematurity

Big Molecule Watch · February 14, 2023

Biosimilar Clinical Trial Updates

Big Molecule Watch · February 14, 2023

Amgen Launches AMJEVITA—First Biosimilar to HUMIRA in the United States

Big Molecule Watch · February 1, 2023

PTAB Issues Final Written Decisions Finding Claims of Regeneron’s Aflibercept Patents Invalid

Big Molecule Watch · November 11, 2022